ASSESSMENT OF THE FRACTURE RISK THROUGH FRACTURE RISK ASSESSMENT TOOL (FRAX) IN POSTMENOPAUSAL WOMEN
Vol. 29 No. 4 (2021), Original Articles
Vol. 29 No. 4 (2021)

ASSESSMENT OF THE FRACTURE RISK THROUGH FRACTURE RISK ASSESSMENT TOOL (FRAX) IN POSTMENOPAUSAL WOMEN

Original Articles
https://doi.org/10.35465/29.4.2021.pp40-46
Published October 25, 2021
Elena Kirilova
University “Prof. Dr. Assen Zlatarov”, Medical Faculty – Burgas, Bulgaria
Stoyanka Vladeva
Trakia University
PDF EN
PDF BG (Български)

Keywords

FRAX, fracture risk, women, menopause

How to Cite

Kirilova, E., & Vladeva, S. (2021). ASSESSMENT OF THE FRACTURE RISK THROUGH FRACTURE RISK ASSESSMENT TOOL (FRAX) IN POSTMENOPAUSAL WOMEN. Rheumatology (Bulgaria), 29(4), 40-46. https://doi.org/10.35465/29.4.2021.pp40-46
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Current National Osteoporosis Foundation (NOF) guidelines recommend treating patients with a 10-year fracture risk (FRAX) of ≥3% for hip fractures or ≥20% for major osteoporotic fractures to reduce the future fracture risk. The present study investigated the distribution of the women in the groups with a FRAX score for major osteoporotic fractures below 20% and for hip fractures below 3%, as well as a FRAX score for major osteoporotic fractures ≥20% and for hip fractures ≥3%. We found that women with a fracture risk corresponding to a FRAX score for major osteoporotic fractures ≥20% and with a FRAX score for hip fractures ≥3% were significantly older (p = 0.000) and had significantly lower weight and height (p = 0.000) compared to women with FRAX score for major osteoporotic fractures below 20% and with a FRAX score for hip fractures below 3%. Regarding the risk factors studied, women with a history of rheumatoid arthritis who currently use corticosteroids have the highest risk of fractures with a FRAX score for major osteoporotic fractures ≥20% and a FRAX score for hip fractures ≥3%.

https://doi.org/10.35465/29.4.2021.pp40-46
PDF EN
PDF BG (Български)

References

  1. Abedinov F, Bakalova N, Krastev P, Petrov I, Marinova R, Tsaryanski G. Survival and Quality of Life of Patients with a Prolonged Stay in the Intensive Care Unit after Cardiac Surgeries–Remote Results. Copt. Rend. Acad. Bulg. Sci. 2019 Jan 1;72:1130-6.
  2. Кирилов Н, И. Шейтанов. Хранителен статус при възрастни жени с ниско ниво на витамин д и остеопороза. Science & echnologies. Volume viii, 2018, number 1: medical bi-ology studies, clinical studies, social medicine and health care, 60-66.
  3. Buchbinder R, Johnston RV, Rischin KJ, Homik J, Jones CA, Golmohammadi K, Kallmes DF. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev. 2018.
  4. Kirilov N, Todorov S, Nikolov N, Nikolov M. COMPARSION OF THE FRACTURE RISK IN WOMEN WITH AND WITHOUT SCOLIOSIS THROUGH DUAL-ENERGY X-RAY ABSOPRTIOMETRY, EULAR 2020, ARD, Ann Rheum Dis, volume 79, supplement 1.
  5. Kirilov N. MOBILE HEALTH APPLICATIONS FOR MANAGEMENT OF MUSCULOSKELETAL DISEASES 2020,Industrial Technologies 7,Vol 1,80-83.
  6. Kirilov N. APPLICATION OF CANNY ALGORITHM IN COMPUTER VISION 2020,Industrial Technologies 7,Vol 1,75-80.
  7. Кirilov N, Kirilova E, Computer vision for assessment of scoliosis from dual energy X-ray (DXA) image Сборник доклади, стр. 18, Втора научна сесия „Биомедицина и качество на живот“ за млади учени, докторанти и постдокторанти в чест на 150‐та годишнина на Българска академия на науките.Институт по биофизика и биомедицинско инженерство – БАН 4 – 5 ноември 2019.
  8. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). 2013.
  9. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; UK: 2007.
  10. Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25. doi:10.1007/s11657-016-0278-z
  11. Kanis, J.A.; Johnell, O.; Oden, A.; Johansson, H.; McCloskey, E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 2008, 19, 385–397.
  12. Kanis, J.A.; McCloskey, E.; Johansson, H.; Oden, A.; Leslie, W.D. FRAX with and without bone mineral density. Calcif. Tissue Int 2012, 90, 1–13.
  13. Aubry-Rozier B, Stoll D, Krieg MA, Lamy O, Hans D. What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture.ClinRheumatol 2013;32:219-23. [CrossRef]
  14. Bolland MJ, Grey A, Gamble G, Reid IR. Comment on Kanis et al.: Pitfalls in the external validation of FRAX. Osteoporos Int2013;24:389- 90. [CrossRef]
  15. Gadam RK, Schlauch K, Izuora KE. Frax prediction without BMD for assessment of osteoporotic fracture risk. EndocrPract. 2013;19(5):780–784. doi:10.4158/EP12416.OR.
  16. Klop C, de Vries F, Bijlsma JWJ, et al. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Annals of the Rheumatic Diseases 2016; 75:2095-2100.
  17. Armstrong ME, Spencer EA, Cairns BJ, Banks E, Pirie K, Green J, et al. Body mass index and physical activity in relation to the incidence of hip fracture in postmenopausal women. J Bone Miner Res. 2011;26((6)):1330–8. doi: 10.1002/jbmr.315.
  18. Gao G, Zhang ZL, Zhang H, Hu WW, Huang QR, Lu JH, et al. Hip axis length changes in 10,554 males and females and the association with femoral neck fracture. J ClinDensitom. 2008;11((3)):360–6. doi: 10.1016/j.jocd.2008.04.005. [PubMed] [CrossRef] [Google Scholar]
  19. World Health Organisation. WHO Technical Report Series 843. In Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis; WHO: Geneva, Switzerland, 1994.
  20. Nguyen, N.D.; Eisman, J.A.; Center, J.R.; Nguyen, T.V. Risk factors for fracture in nonosteoporotic men and women. J. Clin. Endocrinol. Metab. 2007, 92, 955–962. Osteoporos Int. 2013 Jan; 24(1):23-57.
  21. Pasco, J.A.; Seeman, E.; Henry, M.J.; Merriman, E.N.; Nicholson, G.C.; Kotowicz, M.A. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos. Int. 2006, 17, 1404–1409.
  22. Prawiradilaga RS, Gunmalm V, Lund-Jacobsen T, et al. FRAX Calculated without BMD Resulting in a Higher Fracture Risk Than That Calculated with BMD in Women with Early Breast Cancer. J Osteoporos. 2018;2018: 4636028. Published 2018 Oct 4. doi:10.1155/2018/4636028
  23. Briot K, Paternotte S, Kolta S, et al. FRAX®: prediction of major osteoporotic fractures in women from the general population: the OPUS study. PLoS One. 2013;8(12):e83436.
  24. Marques A, Lucas R, Simões E, et al. Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD Open 2017;3: e000509. doi: 10.1136/rmdopen-2017-000509.
  25. Morin SN, Lix LM, Leslie WD. The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women. J Bone Miner Res. 2014 Jul;29(7):1675-80. doi: 10.1002/jbmr.2204.
  26. Kim SY, Schneeweiss S, Liu J, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(4): R154. doi:10.1186/ar3107.
  27. TerposE, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis P.P. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. 2011.
  28. Van Staa TP, GeusensP, Bijlsma J.W, Leufkens H.G, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum, 54 (2006), pp. 3104-3112.
  29. Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB; FRAX(®) Position Development Conference Members. Official Positions for FRAX clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX of the 10-year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. J ClinDensitom. 2011 Jul-Sep;14(3):212-9. doi: 10.1016/j.jocd.2011.05.014.
  30. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011 Mar;22(3):809-16. doi: 10.1007/s00198-010-1524-7. Epub 2011 Jan 13.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.